IGWM
CRVS icon

ICA Group Wealth Management’s Corvus Pharmaceuticals CRVS Stock Holding History

ICA Group Wealth Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-165
Closed -$294 – 878
2024
Q1 		$294 Buy
+165
New +$345 ﹤0.01% 1311

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TL
TowerView LLC New York $155M AUM 30.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ICA Group Wealth Management's CRVS Position: Q2 2024 in Review

ICA Group Wealth Management sold out of Corvus Pharmaceuticals (CRVS) in Q2 2024, closing a stake of 165 shares — an estimated $294 sold.

ICA Group Wealth Management first reported a position in CRVS in Q1 2024 and held it in 1 quarter. The position peaked at $294 in Q1 2024. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2024.

  • ICA Group Wealth Management reported no remaining Corvus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 165 Corvus Pharmaceuticals shares in Q2 2024, an estimated $294.
  • ICA Group Wealth Management first reported a position in Corvus Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • ICA Group Wealth Management's Corvus Pharmaceuticals position peaked at $294 in Q1 2024.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.